Gastric acid secretion inhibitors proton-pump inhibition

Proton pump inhibitors cause a profound and long-lasting inhibition of gastric acid secretion therefore, proton pump inhibitors may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, ampicillin, iron salts, digoxin, cyanocobalamin). 

The reduction of pain and other symptoms due to peptic ulceration may be quite closely linked to the current effect of a drug on acid secretion, but the rate of healing and eventual disappearance of an ulcer is a slow process, determined in part by the extent and duration of gastric acid secretion suppression over several weeks. The clinical response of ulcer healing is therefore a consequence of the cumulative degree of acid inhibition. Proton pump inhibitors such as omeprazole bind irreversibly to the proton pump to suppress gastric acid secretion. The extent of inhibition is close to 100% and responses are related to cumulative effects, but the irreversible nature of the drug action means that schedule dependence is not observed. 

Proton pump inhibitors (gastric acid secretion inhibitors, gastric add pump inhibitors) inhibit gastric acid secretion 90% greater than the H2 blockers because they block the final step of acid production. Both omeprazole (Prilosec) and lansoprazole (Prevacid) are proton pump inhibitors used for the treatment of peptic ulcers and GERD. Those with hepatic impairment should take these drags with caution and have liver enzymes monitored regularly. 

Omeprazole is an antiulcer drug. It is a proton pump inhibitor. This substituted benzimidazole inhibits gastric acid secretion to help acid/peptic disorders and duodenal ulcers. It interferes with the proton pump in the mucous lining of the stomach, the last stage of acid production. It can turn off stomach acid in as little as one hour. Lansoprazole (no. 12) has a similar structure. 

Mechanism of Action A proton pump inhibitor that selectively Inhibits the parietal cell membrane enzyme system (hydrogen-potassium adenosine triphosphatase) or proton pump. Therapeutic Effect Suppresses gastric acid secretion. Pharmacokinetics ... 

Pantoprazole sodium, a substituted benzimidazole derivative, is an irreversible proton pump inhibitor, and was developed for the treatment of acid-related gastrointestinal disorders. As with other drugs of its class (e. g. omeprazol or lansoprazole), pantoprazole reduces gastric acid secretion through inhibition of the portion on the gastric parietal cell. In combination with other drugs, pantoprazole can be used for the initial treatment of H. Pylori infection [1],... 

Proton pump inhibitors Proton pump inhibitors block the final step of acid production and inhibit gastric acid secretion greater than the H2 blockers. Monitor liver enzymes if patient has liver function problems. Examples are ... 

Omeprazole is a selective proton pump inhibitor it directly inhibits the H+/K+ ATPase of the parietal cells of the stomach responsible for gastric acid secretion, and blocks the terminal secretion process of gastric acid. It has a more prolonged effect on acid suppression than H2-antagonists and a short course can give up to several weeks remission from recurrent attacks. 

Omeprazole belongs to a new class of antisecretory compounds, the snbstitnted benzimidazoles, that do not exhibit anticholinergic or H2-histamine-antagonistic properties bnt suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory snrface of the gastric parietal cell. Because this enzyme system is the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid pump inhibitor it blocks the final step of acid prodnction. This effect is dose-related, and inhibits both basal and stimnlated acid secretion irrespective of the stimnlns. 

Proton pump inhibitors (PPIs) reduce gastric acid production in a pronounced and sustained manner. They are the most potent of the drugs that inhibit gastric acid secretion and are now widely used, essentially replacing the formerly heavily used histamine H2-receptor antagonists. 

The answer is d. (Hardman 7 pp 907—909J The main action of omeprazole is the inhibition of secretion of gastric acid Because it is a specific inhibitor of the proton pump (H+,K+,ATPase), other actions are secondary to the marked decline of acid secretion. As a result of the reduction of gastric acidity, there is increased secretion of gastrin leading to hyper-gastrinemia. 

Omeprazole (p. 167) can cause maximal inhibition of HCl secretion. Given orally in gastric juice-resistant capsules, it reaches parietal cells via the blood. In the acidic milieu of the mucosa, an active metabolite is formed and binds covalently to the ATP-driven proton pump (H+/K+ ATPase) that transports H+ in exchange for IC into the gastric juice. Lansoprazole and pantoprazole produce analogous effects. The proton pump inhibitors are first-line drugs for the treatment of gastroesophageal reflux disease. 

At neutral pH proton pump inhibitors are chemically stable, lipid-soluble, weak bases that have no inhibitory activity. In an acid environment they become protonated and a sulfenamide is formed. This sulfenamide binds covalently to the K+H+-ATPase proton pump in the gastric parietal cells, inhibiting this enzyme irreversibly and thus the entry of H+ ions into lumen. Omeprazole metabolizes at a pH of about 3.9. 1, whereas rabeprazole metabolizes at a pH of about 4.9. Secretion of acid only becomes possible again after new molecules of K+H+-ATPase are formed. 

Omeprazole inhibits the secretion of gastric acid and acts as a proton pump inhibitor. It is highly effective for ulcerative reflux esophagatis and peptic ulcer... 

Pharmaceutical inhibition of gastric acid output (proton pump inhibitor, H2 receptor blocker) may have beneficial effects when combined with an unprotected pancreatin preparation, not only by protection of enzymes during their gastric passage, but also by increasing duodenal pH and thereby improving enzymatic action. (Note that, in chronic pancreatitis, duodenal pH is lower due to impairment of pancreatic bicarbonate secretion, see above). 

BY 1023/SK F 96022 INN pantoprazoie, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions./. Pharmacol. Exp. Ther., 1990, 254(1), 129-135. 

Proton pump inhibitors inhibit the H/K-ATPase (proton pump) in oxyntic cells of the stomach, the final common pathway in the secretion of gastric acid in response to a variety of stimuli, such as gastrin and histamine. Their use in acid-related disorders has been extensively reviewed (1-3). 

---